Newton Biocapital heads for year-end close for second, EUR 150m life sciences fund
Newton Biocapital, a Belgian-Japanese venture capital firm focused on life sciences, is heading for a EUR 150m close for its second fund by year-end, and is open to commitments from institutional investors, managing partner Pierre Detrixhe and scientific director Tomoko Asaoka told Unquote.
More on Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds
Iron Wolf Capital targets EUR 70m for second vehicle
Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups
Siena aims to hold new VC secondaries fund first close in late 2023 or early 2024
Secondary investments specialist will target EUR 30m to EUR 50m for new fund
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds